Clinical Trial Update: An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A. [Phase 3]

View source ↗

Summary

A Phase 3 open-label study evaluated the safety and efficacy of recombinant human Coagulation Factor VIII-Fc fusion protein for injection in adolescents and adu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Recombinant human Coagulation Factor VIII-Fc fusion protein for injection (Factor VIII-Fc fusion protein)

Snippet

Sponsor: Zhengzhou Gensciences Inc | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED